Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Coherus Oncology (CHRS) Accumulated Depreciation & Amortization (2016 - 2025)

Coherus Oncology's Accumulated Depreciation & Amortization history spans 13 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 18.75% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 18.75%, while the annual FY2025 figure was $1.3 million, 18.75% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $1.3 million at Coherus Oncology, up from $1.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $19.0 million in Q3 2021 and bottomed at $400000.0 in Q3 2024.
  • The 5-year median for Accumulated Depreciation & Amortization is $950000.0 (2022), against an average of $3.2 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization crashed 95.27% in 2022 before it skyrocketed 150.0% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.5 million in 2021, then rose by 2.86% to $3.6 million in 2022, then fell by 11.11% to $3.2 million in 2023, then crashed by 50.0% to $1.6 million in 2024, then decreased by 18.75% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Accumulated Depreciation & Amortization are $1.3 million (Q4 2025), $1.0 million (Q3 2025), and $700000.0 (Q2 2025).